Cantel Medical's Mar Cor Purification Subsidiary Acquires Hemodialysis Water Business from Siemens' Water Technologies Business

 Cantel Medical's Mar Cor Purification Subsidiary Acquires Hemodialysis Water
           Business from Siemens' Water Technologies Business Unit

Further Expanding Mar Cor's Leadership of the Medical Water Industry

PR Newswire

LITTLE FALLS, N.J., March 25, 2013

LITTLE FALLS, N.J., March 25, 2013 /PRNewswire/ --CANTEL MEDICAL CORP. (NYSE:
CMN), through its Mar Cor Purification subsidiary, has continued the expansion
of its water purification and filtration unit with the purchase of the
hemodialysis water business from Siemens' Water Technologies business unit.
With approximately 600 dialysis customers in the United States and Canada and
2012 revenue of approximately $9 million, this acquisition significantly
expands Mar Cor Purification's North American footprint. The acquisition is
expected to be slightly accretive to Cantel Medical's earnings per share in
fiscal year 2013 and beyond.

Curtis Weitnauer, President and CEO of Mar Cor Purification, stated, "The
acquisition of the Siemens hemodialysis water customer base enables Mar Cor to
realize increased efficiencies from our existing field service operations
while also expanding our footprint into new geographies. With this geographic
expansion, Mar Cor will further improve its ability to service its large
national customers. We look forward to continuing to provide our unique
dialysis products and services to our new and existing customers."

Cantel Medical's President and CEO, Andrew Krakauer, added, "This acquisition
strengthens our position as a leading provider of water purification products
and services to the dialysis industry. Our advanced heat-based disinfection
water technology coupled with our nationwide service footprint makes Mar Cor
the best choice for infection prevention and control to our dialysis
customers. We remain confident that our water purification and filtration
segment will continue to demonstrate industry leading performance."

About Mar Cor Purification, Inc.

A subsidiary of Cantel Medical Corp., Mar Cor Purification is dedicated to
providing innovative solutions through filtration, water purification, and
disinfection technologies to the medical, life science and industrial
marketplaces. Mar Cor Purification has service offices in 22 cities in the
U.S. and Canada, with 7 resin regeneration plants strategically located in
Atlanta, Boston, Chicago, Philadelphia, San Antonio, Montreal and Toronto. For
more information please visit 

About Cantel Medical Corp.

Cantel Medical Corp. (NYSE:CMN) is a leading provider of infection prevention
and control products in the healthcare market. Our products include water
purification equipment, sterilants, disinfectants and cleaners, specialized
medical device reprocessing systems for endoscopy and renal dialysis,
disposable infection control products primarily for dental and GI endoscopy
markets, dialysate concentrates and other dialysis supplies, hollow fiber
membrane filtration and separation products for medical and non-medical
applications, and specialty packaging for infectious and biological specimens.
We also provide technical maintenance for our products and offer compliance
training services for the transport of infectious and biological specimens.

This press release contains forward-looking statements within the meaning of
the Private Securities Litigation Reform Act of 1995. These statements involve
a number of risks and uncertainties, including, without limitation, the risks
detailed in Cantel's filings and reports with the Securities and Exchange
Commission. Such forward-looking statements are only predictions, and actual
events or results may differ materially from those projected or anticipated.

SOURCE Cantel Medical Corp.

Contact: Andrew Krakauer, President and CEO, Cantel Medical Corp., (973)
890-7220, or Richard E. Moyer, Cameron Associates, Inc., (212) 554-5466,
Press spacebar to pause and continue. Press esc to stop.